This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 15, 2014
- BioPharm International-11-15-2014
- Volume 2104 eBook
- Issue 4
Budgets Increase to Support Single-Use Bioprocessing
Author(s)Eric Langer
Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.
Advertisement
Biopharma continues to adopt single-use technologies, but also seeks more innovation and improvements in products.
Articles in this issue
almost 12 years ago
Innovations in Single-Use Bioprocessing Componentsalmost 12 years ago
Optimizing Resin Performance with Disposable Chromatography Solutionsalmost 12 years ago
Security of the Single-Use Supply Chain: Is Dual Sourcing the Answer?almost 12 years ago
Trends in Single-Use BioreactorsAdvertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
5